mtrfr Antibody

What is MTHFR and why are antibodies against it important for research?

MTHFR (Methylenetetrahydrofolate reductase) is an enzyme that catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which serves as a cosubstrate for homocysteine remethylation to methionine. This enzymatic activity represents a key regulatory connection between the folate and methionine cycles in cellular metabolism . The human canonical MTHFR protein consists of 656 amino acid residues with a molecular mass of approximately 74.6 kDa, with up to two different isoforms reported . Antibodies against MTHFR are crucial research tools that enable scientists to detect, quantify, and characterize this enzyme in various experimental contexts, contributing to our understanding of its role in normal physiology and disease states . The importance of these antibodies has grown as research has established connections between MTHFR variations and multiple conditions including vascular diseases, neural tube defects, Alzheimer's disease, and various cancers .

What are the common applications for MTHFR antibodies in laboratory research?

MTHFR antibodies serve multiple experimental purposes across different research applications. Western Blotting (WB) represents one of the most common applications, typically using dilutions around 1/500 to detect MTHFR protein in cell or tissue lysates, with a predicted band size of approximately 75 kDa . Immunohistochemistry on paraffin-embedded tissues (IHC-P) allows researchers to visualize MTHFR distribution within tissue architecture, often using dilutions around 1/100 . Immunocytochemistry/Immunofluorescence (ICC/IF) enables subcellular localization studies in cultured cells . Enzyme-Linked Immunosorbent Assay (ELISA) provides quantitative measurement of MTHFR levels . Immunoprecipitation (IP) allows isolation of MTHFR protein complexes to study protein-protein interactions . These diverse applications provide researchers with a comprehensive toolkit to investigate MTHFR in various experimental contexts, from protein expression analysis to spatial distribution studies within cells and tissues.

How do researchers validate the specificity of MTHFR antibodies?

Validating antibody specificity is a critical step to ensure experimental reproducibility and reliability. For MTHFR antibodies, researchers employ several complementary validation strategies. Western blotting typically serves as the initial validation method, where researchers confirm the detection of bands at the expected molecular weight (~75 kDa for MTHFR) . Positive and negative controls are essential, with HEK-293T and HeLa cell lysates frequently used as positive controls for human MTHFR detection . Recombinant protein overexpression systems can further validate specificity by demonstrating increased signal with increased MTHFR expression . Knockout or knockdown approaches using CRISPR-Cas9 or siRNA techniques provide powerful negative controls, as the antibody signal should decrease substantially or disappear in these samples . Cross-reactivity testing across multiple species helps determine the antibody's species specificity, with some MTHFR antibodies demonstrating reactivity to both human and mouse MTHFR . Researchers should also perform peptide competition assays, where pre-incubation of the antibody with the immunizing peptide should abolish specific binding if the antibody is truly specific.

What are the technical considerations for using MTHFR antibodies in Western blotting?

When using MTHFR antibodies for Western blotting, several technical considerations must be addressed to achieve optimal results. Sample preparation is critical, with complete protein denaturation typically required using reducing agents and heat treatment, as MTHFR's native structure may mask epitopes . Researchers should optimize antibody dilution, with commonly reported dilutions for MTHFR antibodies being around 1/500 for Western blotting . The choice of detection system impacts sensitivity, with enhanced chemiluminescence (ECL) commonly used, but fluorescent secondary antibodies offering advantages for quantitative analysis . Expected band size verification is essential, with MTHFR typically appearing at approximately 75 kDa, though isoforms and post-translational modifications may result in multiple bands . Researchers should also consider loading controls appropriate for their experimental question, such as housekeeping proteins (β-actin, GAPDH) for total protein normalization, or organelle-specific markers if examining MTHFR in subcellular fractions. Transfer efficiency verification using reversible total protein stains helps ensure consistent protein transfer to the membrane before immunodetection.

What are the different types of MTHFR antibodies available for research?

Researchers have access to several types of MTHFR antibodies, each with distinct characteristics suitable for different research applications. Polyclonal antibodies represent the most common type, typically raised in rabbits against recombinant human MTHFR protein or specific peptide regions . These antibodies recognize multiple epitopes on the MTHFR protein, potentially increasing detection sensitivity but with possible batch-to-batch variation . Monoclonal antibodies, though less commonly reported in the literature for MTHFR, offer higher specificity for single epitopes and greater consistency between production lots. Regarding species reactivity, antibodies with confirmed reactivity to human MTHFR are most prevalent, with some also cross-reacting with mouse MTHFR . The immunogen used for antibody production varies, with some generated against full-length recombinant protein and others against specific regions, such as amino acids 1-100 or the C-terminus . Conjugated antibodies (fluorophore or enzyme-linked) for direct detection are available but less common than unconjugated primary antibodies used with separate detection systems .

How can MTHFR antibodies be used to investigate the role of MTHFR in cancer biology?

MTHFR antibodies serve as essential tools for investigating this enzyme's complex role in cancer biology through multiple experimental approaches. Immunohistochemistry using validated MTHFR antibodies allows researchers to analyze MTHFR expression patterns across different tumor types and stages, with recent studies demonstrating significantly lower MTHFR expression in 17 tumor types compared to normal tissues . This technique has been successfully employed with antibodies such as HPA076180 and HPA077255, which have been verified across 20 different tumor types . Researchers can investigate MTHFR's association with tumor microenvironment by combining MTHFR immunostaining with markers for specific immune cell populations, building on findings that MTHFR expression correlates significantly with 67 types of immune cell infiltration scores across 44 cancer types . For mechanistic studies, co-immunoprecipitation experiments using MTHFR antibodies can identify protein-protein interactions within cancer cells, potentially revealing new molecular pathways . Western blotting with MTHFR antibodies allows quantitative comparison of expression levels between tumor and normal tissue lysates, or across different treatment conditions, typically using dilutions around 1/500 .

What methodological approaches enable the study of MTHFR's role in tumor microenvironment?

Studying MTHFR's role in the tumor microenvironment requires sophisticated methodological approaches utilizing MTHFR antibodies. Multiplex immunofluorescence represents a powerful technique where MTHFR antibodies are combined with markers for different cell types (CD4+ T cells, CD8+ T cells, macrophages) on the same tissue section, allowing spatial relationship analysis between MTHFR-expressing cells and immune infiltrates . Laser capture microdissection followed by Western blotting with MTHFR antibodies enables researchers to analyze MTHFR expression specifically in tumor cells versus stromal components, providing insights into compartment-specific MTHFR functions . Flow cytometry using fluorophore-conjugated MTHFR antibodies permits quantitative analysis of MTHFR expression in different cell populations isolated from tumor samples . Single-cell RNA sequencing combined with protein validation using MTHFR antibodies can reveal heterogeneity in MTHFR expression across different cell types within the tumor microenvironment . Researchers have demonstrated significant correlations between MTHFR expression and biomarkers of immune-related genes (CD19, CD274, CD80, CD86) across multiple cancer types, suggesting MTHFR's importance in immune regulation within tumors .

How can MTHFR antibodies contribute to understanding the relationship between MTHFR polymorphisms and disease?

MTHFR antibodies offer valuable methodological approaches to investigate how MTHFR polymorphisms affect protein expression, function, and disease associations. Researchers can employ Western blotting with MTHFR antibodies to compare protein expression levels in samples with different MTHFR genotypes (e.g., 677CC, 677CT, 677TT), correlating genetic variation with protein abundance . Enzymatic activity assays combined with immunoprecipitation using MTHFR antibodies allow direct assessment of how polymorphisms affect MTHFR function, building on knowledge that enzyme efficiency is reduced by up to 45% for the 677CT variant and by up to 70% for 677TT . Immunohistochemistry using MTHFR antibodies in tissue samples from individuals with known MTHFR genotypes can reveal how polymorphisms affect tissue-specific expression patterns . For clinical correlation studies, researchers combine genotyping with MTHFR protein quantification using validated antibodies to establish stronger genotype-phenotype relationships in various diseases . The implementation of tissue microarrays with MTHFR antibody staining facilitates high-throughput analysis of MTHFR expression across large cohorts of patients with known genotypes, strengthening statistical power for clinical associations.

What techniques can be used to study MTHFR's potential as a predictive biomarker for immune checkpoint blockade therapy?

Recent research has identified MTHFR as a potential predictive biomarker for immune checkpoint blockade therapy response, with several techniques utilizing MTHFR antibodies being crucial for this research direction. Immunohistochemistry with validated MTHFR antibodies (such as HPA076180 and HPA077255) on pre-treatment biopsies allows researchers to assess whether baseline MTHFR expression correlates with clinical responses to checkpoint inhibitors like nivolumab, pembrolizumab, or ipilimumab . Multiplex immunofluorescence combining MTHFR antibodies with PD-1, PD-L1, and CTLA-4 staining provides insights into the spatial relationships between MTHFR expression and checkpoint molecules within the tumor microenvironment . Receiver Operating Characteristic (ROC) analysis has demonstrated MTHFR's potential as a biomarker in anti-PD-1 (nivolumab and pembrolizumab for melanoma) and anti-CTLA4 (ipilimumab for melanoma) treatment cohorts . Serial biopsies analyzed with MTHFR antibodies during treatment enable monitoring of dynamic changes in MTHFR expression in response to checkpoint blockade, potentially revealing mechanisms of resistance or response . Flow cytometry using fluorophore-conjugated MTHFR antibodies permits analysis of MTHFR expression in specific immune cell populations before and after treatment, providing insights into which immune subsets might be influenced by MTHFR in the context of immunotherapy.

How can researchers optimize immunohistochemical protocols for MTHFR detection in different tissue types?

Optimizing immunohistochemical protocols for MTHFR detection requires careful consideration of multiple methodological factors to ensure consistent and specific staining across different tissue types. Antigen retrieval methods significantly impact MTHFR detection, with heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) commonly employed, requiring empirical determination of optimal conditions for each tissue type . Antibody dilution optimization is essential, with reported dilutions for MTHFR antibodies in IHC typically around 1/100, though this may require adjustment based on tissue type and fixation methods . Blocking protocols should be carefully optimized to minimize background, with bovine serum albumin (BSA) or normal serum from the same species as the secondary antibody commonly used . Detection systems vary in sensitivity, with amplification methods like tyramide signal amplification potentially beneficial for tissues with low MTHFR expression . Validated positive control tissues include normal prostate tissue, which consistently expresses MTHFR and can serve as a technical reference . Researchers should implement careful counterstaining procedures to provide structural context without obscuring specific MTHFR staining, with hematoxylin counterstaining commonly used at optimized intensities.

What is MTRFR and how does it differ from MTHFR?

MTRFR (Mitochondrial translation release factor in rescue), also known as C12orf65 or My030, is a protein that functions in a mitoribosome-associated quality control pathway, which is fundamentally different from MTHFR's role in folate metabolism . MTRFR prevents aberrant translation by responding to interruptions during elongation in mitochondrial protein synthesis, while MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in the folate cycle . Mechanistically, MTRFR forms a heterodimer with MTRES1 to eject unfinished nascent chains and peptidyl transfer RNA from stalled ribosomes, suggesting a specialized role in mitochondrial translation quality control . This function indicates MTRFR's importance in mitochondrial function and potentially in diseases associated with mitochondrial dysfunction, whereas MTHFR primarily influences methylation processes and homocysteine metabolism . From a research antibody perspective, antibodies against these two distinct proteins target entirely different epitopes and should not be used interchangeably, as they recognize proteins with different subcellular localizations, molecular weights, and biological functions .

What are the applications and methodological considerations for using MTRFR antibodies?

MTRFR (C12orf65) antibodies have specific applications and methodological considerations distinct from MTHFR antibodies. Western blotting represents the primary validated application for MTRFR antibodies, requiring careful optimization of sample preparation methods to effectively extract this mitochondrial protein . Researchers should consider specialized lysis buffers that effectively solubilize mitochondrial membranes while preserving protein integrity . Since MTRFR functions in the mitochondrial translation system, subcellular fractionation protocols may be necessary to enrich mitochondrial proteins before Western blotting or immunoprecipitation . When designing experiments, researchers should consider the interaction between MTRFR and MTRES1, potentially employing co-immunoprecipitation techniques to study this functional complex . For immunohistochemistry or immunofluorescence applications, researchers should optimize fixation protocols that preserve mitochondrial architecture while ensuring antibody accessibility . The specificity of MTRFR antibodies should be validated in tissues or cells with known mitochondrial translation defects, which would be expected to show altered MTRFR expression or localization patterns .

How can MTRFR antibodies contribute to understanding mitochondrial translation quality control in disease models?

MTRFR antibodies offer valuable research tools for investigating mitochondrial translation quality control mechanisms in various disease contexts. Neurodegenerative disease models represent important systems for MTRFR investigation, as mitochondrial translation defects have been implicated in conditions like Parkinson's and Alzheimer's disease . Using MTRFR antibodies, researchers can assess whether disruptions in mitochondrial quality control pathways correlate with disease progression through Western blotting of brain tissue samples or immunohistochemistry of affected regions . Cancer cell lines with mitochondrial dysfunction can be probed with MTRFR antibodies to determine whether alterations in mitochondrial translation quality control contribute to metabolic reprogramming in cancer . In models of mitochondrial disease, MTRFR antibodies enable assessment of how pathogenic mutations affect the recruitment and function of quality control factors at stalled mitoribosomes . Researchers can employ MTRFR antibodies in conjunction with markers of mitochondrial stress (like HSP60 or mtHSP70) to investigate how cells respond to disruptions in mitochondrial translation . Co-immunoprecipitation experiments using MTRFR antibodies can identify novel interaction partners involved in mitochondrial quality control, potentially revealing new therapeutic targets for diseases with mitochondrial involvement .

MTHFR Antibody Characteristics and Applications

MTHFR Expression Correlation with Immune Cell Infiltration in Cancer

Recent comprehensive analysis across 44 cancer types has revealed significant correlations between MTHFR expression and immune cell infiltration, highlighting its potential role in tumor immunology . The study demonstrated that MTHFR expression significantly correlates with 67 different types of immune cell infiltration scores across these cancer types, suggesting its importance in shaping the tumor immune microenvironment . Particularly strong correlations were observed with markers of adaptive immunity, including T cell and B cell signatures, which are critical components of anti-tumor immunity . MTHFR expression also showed significant positive correlations with several important immune-related genes, including CD19 (B cell marker), CD274 (PD-L1), CD80, and CD86 (co-stimulatory molecules) . These findings suggest that MTHFR may play a previously unrecognized role in regulating immune responses within tumor tissues, potentially influencing responsiveness to immunotherapies . Notably, MTHFR expression was found to be significantly lower in 17 tumor types compared to normal tissues, suggesting that downregulation of this enzyme may contribute to tumor immune evasion mechanisms .

MTHFR as a Predictive Biomarker for Immune Checkpoint Blockade Response